Evelo Biosciences Announces Grant of Inducement Award
01 sept. 2022 17h15 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
01 sept. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences Announces Succession Plan
11 août 2022 06h01 HE
|
Evelo Biosciences, Inc.
– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search – ...
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
11 août 2022 06h00 HE
|
Evelo Biosciences, Inc.
– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase...
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
05 août 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
18 juil. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
12 mai 2022 10h47 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence...
Evelo Biosciences Appoints John Maraganore, Ph.D. and Tassos Gianakakos as Strategic Advisors
21 avr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...
Evelo Biosciences Provides Updated Guidance on Advancing Clinical Inflammation Programs
14 avr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
–Guidance on registration trials for EDP1815 in psoriasis expected in 3Q 2022––Data from initial cohort of patients in Phase 2 trial of EDP1815 in atopic dermatitis expected 1Q 2023––Faster release...
Evelo Biosciences Announces Appointments of Jose-Carlos Gutiérrez-Ramos and Tonya Williams to Board of Directors
06 avr. 2022 06h00 HE
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today...